Utilization of acute gout prophylaxis in the real world: a retrospective database cohort analysis

ConclusionIn the real world, the proportion of patients who receive AGP with initiation of XOI therapy is low and discontinuation of XOI within 12  months of initiation is significant. In this analysis, use of AGP was not associated with a lower risk of acute gout flare after initiation of XOI therapy.Key Points•Real-world acute gout prophylaxis (AGP) prescribing with xanthine oxidase inhibitor (XOI) initiation is very low despite current guideline recommendations•More than one third of patients discontinue XOIs within 12  months of initiation regardless of AGP prescribing
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research